UK-based drug development services company Quotient Bioresearch has hooked up with US testing laboratory CRL to offer global clinical laboratory capabilities to clients in the pharmaceutical, biotechnology and contract research sectors.

Under the agreement, Quotient and Kansas-based Clinical Reference Laboratory (CRL Global Services) are pooling their clinical laboratory and other specialist testing services, which the two companies describe as “entirely complementary”.

As part of the deal, CRL Global Services will set up its European clinical reference laboratory operation at Quotient’s UK facility in Cambridge, making it the European hub for CRL’s Central Laboratory Services unit. This will complement Quotient’s existing clinical laboratory services, particularly in the field of bioanalysis and biomarkers, the UK company said.

“This collaboration brings exciting new opportunities for our bioanalytical sciences and microbiology businesses,” commented Paul Cowan, chief executive officer (CEO) of Quotient Bioresearch. “Working in tandem with CRL offers access to a well-established, standardised global laboratory infrastructure and the ability to serve the requirements of our clients for global clinical trials.”

Tim Sotos, CEO of Clinical Reference Laboratory, pointed to Quotient’s strong track record in high-quality bioanalytical sciences and early-phase drug development, which were “highly complementary to our business” and offered “significant added value in the provision of central laboratory services”.

CRL is characterised as “one of the largest privately owned laboratories operating on a national basis in the USA”. Its testing services extend from clinical trials to corporate wellness programmes, genomics, insurance and toxicology.